scholarly journals Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination

2020 ◽  
Vol 222 (Supplement_7) ◽  
pp. S688-S694
Author(s):  
Michiel van Boven ◽  
Anne C Teirlinck ◽  
Adam Meijer ◽  
Mariëtte Hooiveld ◽  
Christiaan H van Dorp ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Young Children ◽  
Hospital Admissions ◽  
Respiratory Infections ◽  
Parameter Estimates ◽  
Syncytial Virus ◽  
And Shifts ◽  
Pediatric Vaccination ◽  
The Impact ◽  
Transmission Models

Abstract Background Respiratory syncytial virus (RSV) is a leading cause of respiratory tract illness in young children and a major cause of hospital admissions globally. Methods Here we fit age-structured transmission models with immunity propagation to data from the Netherlands (2012–2017). Data included nationwide hospitalizations with confirmed RSV, general practitioner (GP) data on attendance for care from acute respiratory infection, and virological testing of acute respiratory infections at the GP. The transmission models, equipped with key parameter estimates, were used to predict the impact of maternal and pediatric vaccination. Results Estimates of the basic reproduction number were generally high (R0 > 10 in scenarios with high statistical support), while susceptibility was estimated to be low in nonelderly adults (<10% in persons 20–64 years) and was higher in older adults (≥65 years). Scenario analyses predicted that maternal vaccination reduces the incidence of infection in vulnerable infants (<1 year) and shifts the age of first infection from infants to young children. Conclusions Pediatric vaccination is expected to reduce the incidence of infection in infants and young children (0–5 years), slightly increase incidence in 5 to 9-year-old children, and have minor indirect benefits.

scholarly journals Respiratory Syncytial Virus Disease Severity in Young Children

2020 ◽  
Author(s):  
Zaid Haddadin ◽  
Stockton Beveridge ◽  
Kailee Fernandez ◽  
Danielle A Rankin ◽  
Varvara Probst ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Young Children ◽  
Disease Severity ◽  
Severity Score ◽  
Respiratory Infections ◽  
Virus Disease ◽  
Younger Age ◽  
Inpatient Settings ◽  
Syncytial Virus

Abstract Background Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infections (ARIs) in hospitalized children. Although prematurity and underlying medical conditions are known risk factors, most of these children are healthy, and factors including RSV load and subgroups may contribute to severity. Therefore, we aimed to evaluate the role of RSV in ARI severity and determine factors associated with increased RSV-ARI severity in young children. Methods Children aged <5 years with fever and/or ARI symptoms were recruited from the emergency department (ED) or inpatient settings at Vanderbilt Children’s Hospital. Nasal and/or throat swabs were tested using quantitative reverse-transcription polymerase chain reaction for common respiratory viruses, including RSV. A severity score was calculated for RSV-positive children. Results From November 2015 through July 2016, 898 participants were enrolled, and 681 (76%) had at least 1 virus detected, with 191 (28%) testing positive for RSV. RSV-positive children were more likely to be hospitalized, require intensive care unit admission, and receive oxygen compared with children positive for other viruses. Higher viral load, White race, younger age, and higher severity score were independently associated with hospitalization in RSV-positive children. No differences in disease severity were noted between RSV A and RSV B. Conclusions RSV was associated with increased ARI severity in young children enrolled from the ED and inpatient settings, but no differences in disease severity were noted between RSV A and RSV B. These findings emphasize the need for antiviral therapy and/or preventive measures such as vaccines against RSV in young children.

scholarly journals Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets

2020 ◽  
Vol 222 (Supplement_7) ◽  
pp. S599-S605
Author(s):  
Rachel M Reeves ◽  
Maarten van Wijhe ◽  
Sabine Tong ◽  
Toni Lehtonen ◽  
Luca Stona ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Hospital Admissions ◽  
European Countries ◽  
Hospital Data ◽  
Admission Rates ◽  
Time Series Modelling ◽  
Modelling Methodology ◽  
Syncytial Virus ◽  
Future Work ◽  
The Impact

Abstract Background Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infection (RTI) in young children. Registries provide opportunities to explore RSV epidemiology and burden. Methods We explored routinely collected hospital data on RSV in children aged < 5 years in 7 European countries. We compare RSV-associated admission rates, age, seasonality, and time trends between countries. Results We found similar age distributions of RSV-associated hospital admissions in each country, with the highest burden in children < 1 years old and peak at age 1 month. Average annual rates of RTI admission were 41.3–112.0 per 1000 children aged < 1 year and 8.6–22.3 per 1000 children aged < 1 year. In children aged < 5 years, 57%–72% of RTI admissions with specified causal pathogen were coded as RSV, with 62%–87% of pathogen-coded admissions in children < 1 year coded as RSV. Conclusions Our results demonstrate the benefits and limitations of using linked routinely collected data to explore epidemiology and burden of RSV. Our future work will use these data to generate estimates of RSV burden using time-series modelling methodology, to inform policymaking and regulatory decisions regarding RSV immunization strategy and monitor the impact of future vaccines.

scholarly journals The return of the RSV

2021 ◽  
Author(s):  
Fernando Ferrero ◽  
Maria Ossorio ◽  
Maria Rial
Keyword(s):  
Respiratory Syncytial Virus ◽  
Southern Hemisphere ◽  
Respiratory Infections ◽  
Mitigation Measures ◽  
Acute Respiratory Infections ◽  
Syncytial Virus ◽  
The Impact

Respiratory syncytial virus (RSV) hospitalizations disappear in 2020. Now, with winter 2021 completely over in southern hemisphere, RSV has returned. Despite it is difficult to measure the impact of pandemic mitigation measures, it appears that the acute respiratory infections in pediatrics are returning to their usual epidemiology.

scholarly journals Impact of hygienic and social distancing measures against SARS-CoV-2 on respiratory infections caused by other viruses

2021 ◽  
Author(s):  
Jordi Reina ◽  
◽  
Ricardo M. Arcay ◽  
María Busquets ◽  
Herminia Machado
Keyword(s):  
Respiratory Syncytial Virus ◽  
Respiratory Infection ◽  
Acute Respiratory Infection ◽  
Respiratory Infections ◽  
Respiratory Viruses ◽  
Contact Material ◽  
Rt Pcr ◽  
Social Distancing ◽  
Syncytial Virus ◽  
The Impact

Introduction. To control the pandemic caused by SARS-CoV-2, the implementation of social and hygienic confinement measures was determined in all countries. These measures reduce the circulation of most respiratory viruses that are transmitted preferentially by air and contact. Material and methods. The impact of these measures on non-Covid respiratory viruses during the period August-December 2020 and 2019 has been comparatively analyzed. To all nasopharyngeal aspirates that were negative against SARS-CoV-2 by RT-PCR and the suspicion of acute respiratory infection persisted, were subjected to a new RT-PCR that simultaneously and differentially amplifies 21 different respiratory viruses. Results. In the year of the pandemic, a 36.6% decrease was detected in the number of respiratory samples studied and 66% in their positivity in relation to 2019. All viruses showed reduction percentages of between 40-100%. The only viruses that circulated during and after national lockdown were rhinovirus (74.1%), adenovirus (10.1%), and enterovirus (9.6%). Conclusion. The measures used to control the SARS-CoV-2 infection have also affected the community circulation of most respiratory viruses including influenza and respiratory syncytial virus.

scholarly journals Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study

2019 ◽  
Vol 36 (S 02) ◽  
pp. S77-S82
Author(s):  
Elena Priante ◽  
Elena Tavella ◽  
Elisa Girardi ◽  
Maria Angela Militello ◽  
Veronica Mardegan ◽  
...  
Keyword(s):  
Gestational Age ◽  
Neonatal Intensive Care ◽  
Hospital Admissions ◽  
Respiratory Infections ◽  
Cost Benefit ◽  
Respiratory Viruses ◽  
Before And After ◽  
Cost Benefit Ratio ◽  
Syncytial Virus ◽  
The Impact

Objective Premature infants have the highest risk of being hospitalized with respiratory syncytial virus (RSV) infections. Palivizumab is the only licensed agent for RSVhospitalization (RSVH) prophylaxis in infants born at < 35 weeks of gestational age (wGA). In 2016, the Italian Drug Agency (Agenzia Italiana del Farmaco [AIFA]) has restricted the eligibility for reimbursement to infants at high risk of RSVH, ruling out palivizumab administration for infants born at > 29 wGA. The aim of the present study was to compare the incidence of RSVH in two consecutive epidemic seasons (2015–2016 vs. 2016–2017), that is, before and after the new AIFA recommendations on palivizumab eligibility. Study Design This was a noninterventional retrospective cohort study conducted at three neonatal intensive care units (NICUs) in northern Italy. Infants born at 29 and 35 wGA between March 15, 2015 and March 14, 2017 were enrolled for this study. Electronic medical charts were reviewed and parents were interviewed by telephone. Data were collected on neonatal course during NICU stay, palivizumab administration, and hospitalizations related to respiratory infections during the 1st year of life, comparing the infants born in season 1 with season 2. Results Of 632 eligible infants, data were available for 536 (262 in season 1 and 274 in season 2). Overall, RSVH occurred 1.9 and 5.1% in infants in seasons 1 and 2, respectively (odds ratio [OR] = 2.77; 95% confidence interval [CI]: 0.98–7.8, p = 0.045). When the analysis was limited to patients not exposed to palivizumab, RSVHs were recorded for 1.8 and 5.9% infants in seasons 1 and 2, respectively (OR = 3.42; 95% CI: 0.96–12.20, p = 0.045). It is noteworthy that the incidence of hospital admissions for respiratory viruses other than RSV did not differ between the two seasons. Conclusion Restricting eligibility for palivizumab reimbursement led to a significant increase in RSVH but had no impact on hospitalizations for other respiratory viruses. Future decisions on palivizumab prescription and coverage rules should be driven by a careful assessment of the cost-benefit ratio.

scholarly journals Global hospital admissions and in-hospital mortality associated with all-cause and virus-specific acute lower respiratory infections in children and adolescents aged 5–19 years between 1995 and 2019: a systematic review and modelling study

2021 ◽  
Vol 6 (7) ◽  
pp. e006014
Author(s):  
Xin Wang ◽  
You Li ◽  
Xin Mei ◽  
Erin Bushe ◽  
Harry Campbell ◽  
...  
Keyword(s):  
Systematic Review ◽  
Respiratory Syncytial Virus ◽  
Hospital Admissions ◽  
Respiratory Infections ◽  
Human Metapneumovirus ◽  
Parainfluenza Virus ◽  
Acute Lower Respiratory Infections ◽  
Hospital Deaths ◽  
Syncytial Virus ◽  
Human Parainfluenza Virus

IntroductionThe burden of acute lower respiratory infections (ALRI), and common viral ALRI aetiologies among 5–19 years are less well understood. We conducted a systematic review to estimate global burden of all-cause and virus-specific ALRI in 5–19 years.MethodsWe searched eight databases and Google for studies published between 1995 and 2019 and reporting data on burden of all-cause ALRI or ALRI associated with influenza virus, respiratory syncytial virus, human metapneumovirus and human parainfluenza virus. We assessed risk of bias using a modified Newcastle-Ottawa Scale. We developed an analytical framework to report burden by age, country and region when there were sufficient data (all-cause and influenza-associated ALRI hospital admissions). We estimated all-cause ALRI in-hospital deaths and hospital admissions for ALRI associated with respiratory syncytial virus, human metapneumovirus and human parainfluenza virus by region.ResultsGlobally, an estimated 5.5 million (UR 4.0–7.8) all-cause ALRI hospital admissions occurred annually between 1995 and 2019 in 5–19 year olds, causing 87 900 (UR 40 300–180 600) in-hospital deaths annually. Influenza virus and respiratory syncytial virus were associated with 1 078 600 (UR 4 56 500–2 650 200) and 231 800 (UR 142 700–3 73 200) ALRI hospital admissions in 5–19 years. Human metapneumovirus and human parainfluenza virus were associated with 105 500 (UR 57 200–181 700) and 124 800 (UR 67 300–228 500) ALRI hospital admissions in 5–14 years. About 55% of all-cause ALRI hospital admissions and 63% of influenza-associated ALRI hospital admissions occurred in those 5–9 years globally. All-cause and influenza-associated ALRI hospital admission rates were highest in upper-middle income countries, Asia-Pacific region and the Latin America and Caribbean region.ConclusionIncidence and mortality data for all-cause and virus-specific ALRI in 5–19 year olds are scarce. The lack of data in low-income countries and Eastern Europe and Central Asia, South Asia, and West and Central Africa warrants efforts to improve the development and access to healthcare services, diagnostic capacity, and data reporting.

Sign in / Sign up

Export Citation Format

Share Document